Moderna Inc (MRNA) Projects $1.9 Billion Revenue for 2025, Shares Surge 12.8%
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 13 2026
0mins
Should l Buy MRNA?
Source: Benzinga
- Revenue Forecast Increase: At the 44th Annual J.P. Morgan Healthcare Conference, Moderna announced an expected revenue of approximately $1.9 billion for 2025, which is $100 million above the previously communicated midpoint, enhancing investor confidence and driving stock price up.
- Operating Expense Improvement: The company also lowered its projected GAAP operating expenses for 2025 by $200 million, demonstrating improved cost control capabilities that lay a solid foundation for future profitability.
- Increased Cash Balance: Moderna anticipates an end-of-year cash balance of approximately $8.1 billion, providing strong support for the company's R&D and market expansion efforts, further solidifying its market position.
- Strong Stock Performance: Following the positive news, Moderna's stock surged 12.8% to $38.20 on Tuesday, reflecting market optimism regarding its future growth potential.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy MRNA?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on MRNA
Wall Street analysts forecast MRNA stock price to fall
20 Analyst Rating
1 Buy
16 Hold
3 Sell
Hold
Current: 52.840
Low
17.00
Averages
32.47
High
63.00
Current: 52.840
Low
17.00
Averages
32.47
High
63.00
About MRNA
Moderna, Inc. is a biotechnology company advancing a new class of medicines made of messenger ribonucleic acid (mRNA). It is engaged in developing medicines across infectious disease vaccines, oncology therapeutics and rare disease therapeutics. Its platform incorporates advances across three components, mRNA, delivery, and the manufacturing process, to advance its medicines. Its products are Spikevax and mNEXSPIKE (its COVID vaccines), and mRESVIA (its vaccine against respiratory syncytial virus (RSV)). It also has a diverse development pipeline that consists of 35 therapeutic and vaccine programs, six of which are in late-stage development. It has regulatory filings under review for its seasonal flu+COVID vaccine (mRNA-1083) in Europe and Canada and for its seasonal flu vaccine (mRNA-1010) in the United States, Europe, Canada and Australia. Its rare disease programs are Propionic acidemia (mRNA-3927); Methylmalonic acidemia (mRNA-3705), and Cystic Fibrosis (mRNA-3692/VX-522).
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
White House Nominates Erica Schwartz as Next CDC Director
- Nomination of Schwartz: The White House is set to nominate Erica Schwartz, who served as deputy U.S. surgeon general under Trump, as the next CDC director, pending Trump's approval, indicating a desire for a nominee who minimizes controversy.
- CDC Leadership Vacancy: The CDC has been without permanent leadership since August when former director Susan Monarez was fired over disagreements with Trump's healthcare policies, which has impacted the agency's policy execution and public trust.
- Schwartz's Background: Schwartz holds a master's degree in public health and a law degree, and her experience as a Navy physician and chief medical officer at the U.S. Coast Guard may bring new perspectives and leadership to the CDC.
- Deputy Director Candidate: The Trump administration is also considering Sean Slovenski, a former Walmart executive, as Schwartz's deputy, further indicating the strategic reshaping of leadership within the CDC.
See More
Citigroup Upgrades U.S. Stocks to Overweight Amid Iran Conflict Outlook
- Optimistic Market Outlook: Citigroup upgraded U.S. stocks to overweight from neutral on Monday, citing the eventual end of the U.S.-Iran conflict as a catalyst for market gains, indicating a positive outlook for year-end equities.
- S&P 500 Recovery: The S&P 500 closed at 6,886.24 on Monday, erasing losses since the conflict began, demonstrating market resilience in the face of geopolitical risks and reflecting a recovery in investor confidence.
- Sector Recommendations: Citigroup recommends investors focus on materials, healthcare, and tech stocks, with materials being the best-performing S&P 500 sector this year, up over 14%, while healthcare stocks like Moderna and DaVita have surged 72% and 33%, respectively, showcasing sector performance disparities.
- Institutional Attitude Shift: Following BlackRock, Citigroup becomes the second major institution this week to adopt a more positive stance on U.S. stocks, signaling growing confidence in the U.S. economic recovery, which may attract more capital inflows into the equity market.
See More
Oil Prices Surge Amid SpaceX's $2 Trillion IPO Buzz
- Oil Price Surge: Current prices for West Texas Intermediate and Brent crude have reached $110 per barrel, marking a 35% increase since December, which significantly impacts American consumers as gasoline prices rise from $2.80 to $3.80 per gallon, increasing economic strain on households.
- Futures Market Dynamics: The oil futures market is experiencing backwardation, with current month prices at $110 per barrel compared to $70 for contracts expiring in late 2026, indicating market concerns about short-term supply issues while suggesting a more optimistic long-term outlook that could influence investor strategies.
- SpaceX IPO Outlook: SpaceX has filed for a confidential IPO, potentially valued at $2 trillion, although the actual capital needed may only be $80 to $100 billion, reflecting strong market interest in the space economy and likely attracting significant investor attention.
- Economic Impact Assessment: Despite the pressure from rising oil prices, recent employment data shows a robust job market with a slight decrease in unemployment, indicating that consumers are maintaining some economic resilience in the face of rising costs, necessitating close monitoring of future economic trends.
See More
Rising Oil Prices and Space Economy Outlook
- Oil Price Surge: Current prices for West Texas Intermediate and Brent crude have reached $110 per barrel, marking a 35% increase since last December, which significantly impacts American consumers as gasoline prices rise from $2.80 to $3.80, potentially affecting the overall economy.
- Futures Market Dynamics: The oil futures market is experiencing backwardation, with current month contracts priced at $110 per barrel while contracts for late 2026 are only $70, indicating that investors believe short-term supply issues may not persist, reflecting expectations for a return to normal pricing.
- Economic Impact Assessment: Despite the pressure from rising oil prices, recent employment data shows a decrease in unemployment, suggesting that consumer confidence remains strong, which may mitigate the negative effects of higher oil prices on the economy.
- Space Economy Potential: SpaceX is seeking a confidential public listing with a potential valuation of $2 trillion; however, the actual funds needed may be significantly lower, indicating strong investor interest in the space sector and its growth prospects.
See More
Salesforce's Transformation and Challenges in the Age of AI
- Cost-Saving Strategy: Morgan DeBaun, CEO of Blavity, anticipates a shift from Salesforce's CRM platform to a more cost-efficient AI solution by early 2027, potentially saving 50% to 60%, highlighting the emphasis on cost-effectiveness in the AI era.
- Expectations for AI Features: DeBaun insists that Salesforce's AI capabilities should be included in the base offering rather than charged separately, indicating dissatisfaction with pricing strategies that could impact Salesforce's competitive position in the market.
- Market Reaction and Stock Volatility: Salesforce's stock has dropped over 35% in the past year, currently trading around $170, reflecting investor concerns about AI tools potentially disrupting traditional enterprise software, leading to a broader sell-off in software stocks.
- Future Outlook and Investment Confidence: Despite challenges, analysts remain bullish on Salesforce, with Citizens maintaining a buy rating and a $315 price target, demonstrating confidence in the company's ability to adapt to the evolving AI landscape.
See More
CDC Report Delay Raises Questions on Vaccine Efficacy
- Vaccine Efficacy Report Delayed: CDC's Jay Bhattacharya has postponed the publication of a report originally scheduled for March 19, which indicated that COVID vaccines could reduce the risk of ER visits and hospitalizations by nearly 50% in healthy adults, raising concerns about vaccine efficacy.
- Methodology Controversy: The study utilized a 'test-negative design' based on data from healthy adults receiving the 2025-2026 vaccine, showing a 50% and 55% reduction in ER visits and hospitalizations, respectively; however, Bhattacharya's concerns about the methodology may undermine public confidence in vaccines.
- Political Interference Concerns: A former CDC official suggested that the vaccine benefits are being downplayed due to the stance of HHS Secretary RFK Jr., who has pushed for restrictions on vaccine availability, potentially affecting the CDC's research publication and public health policy.
- Leadership Review Norm: An HHS spokesperson noted that it is routine for CDC leadership to review and flag concerns regarding study methodologies before publication, highlighting the complex interplay between science and politics in vaccine research dissemination.
See More
White House Nominates Erica Schwartz as Next CDC Director
- Nomination of Schwartz: The White House is set to nominate Erica Schwartz, who served as deputy U.S. surgeon general under Trump, as the next CDC director, pending Trump's approval, indicating a desire for a nominee who minimizes controversy.
- CDC Leadership Vacancy: The CDC has been without permanent leadership since August when former director Susan Monarez was fired over disagreements with Trump's healthcare policies, which has impacted the agency's policy execution and public trust.
- Schwartz's Background: Schwartz holds a master's degree in public health and a law degree, and her experience as a Navy physician and chief medical officer at the U.S. Coast Guard may bring new perspectives and leadership to the CDC.
- Deputy Director Candidate: The Trump administration is also considering Sean Slovenski, a former Walmart executive, as Schwartz's deputy, further indicating the strategic reshaping of leadership within the CDC.
See More
Citigroup Upgrades U.S. Stocks to Overweight Amid Iran Conflict Outlook
- Optimistic Market Outlook: Citigroup upgraded U.S. stocks to overweight from neutral on Monday, citing the eventual end of the U.S.-Iran conflict as a catalyst for market gains, indicating a positive outlook for year-end equities.
- S&P 500 Recovery: The S&P 500 closed at 6,886.24 on Monday, erasing losses since the conflict began, demonstrating market resilience in the face of geopolitical risks and reflecting a recovery in investor confidence.
- Sector Recommendations: Citigroup recommends investors focus on materials, healthcare, and tech stocks, with materials being the best-performing S&P 500 sector this year, up over 14%, while healthcare stocks like Moderna and DaVita have surged 72% and 33%, respectively, showcasing sector performance disparities.
- Institutional Attitude Shift: Following BlackRock, Citigroup becomes the second major institution this week to adopt a more positive stance on U.S. stocks, signaling growing confidence in the U.S. economic recovery, which may attract more capital inflows into the equity market.
See More
Oil Prices Surge Amid SpaceX's $2 Trillion IPO Buzz
- Oil Price Surge: Current prices for West Texas Intermediate and Brent crude have reached $110 per barrel, marking a 35% increase since December, which significantly impacts American consumers as gasoline prices rise from $2.80 to $3.80 per gallon, increasing economic strain on households.
- Futures Market Dynamics: The oil futures market is experiencing backwardation, with current month prices at $110 per barrel compared to $70 for contracts expiring in late 2026, indicating market concerns about short-term supply issues while suggesting a more optimistic long-term outlook that could influence investor strategies.
- SpaceX IPO Outlook: SpaceX has filed for a confidential IPO, potentially valued at $2 trillion, although the actual capital needed may only be $80 to $100 billion, reflecting strong market interest in the space economy and likely attracting significant investor attention.
- Economic Impact Assessment: Despite the pressure from rising oil prices, recent employment data shows a robust job market with a slight decrease in unemployment, indicating that consumers are maintaining some economic resilience in the face of rising costs, necessitating close monitoring of future economic trends.
See More
Rising Oil Prices and Space Economy Outlook
- Oil Price Surge: Current prices for West Texas Intermediate and Brent crude have reached $110 per barrel, marking a 35% increase since last December, which significantly impacts American consumers as gasoline prices rise from $2.80 to $3.80, potentially affecting the overall economy.
- Futures Market Dynamics: The oil futures market is experiencing backwardation, with current month contracts priced at $110 per barrel while contracts for late 2026 are only $70, indicating that investors believe short-term supply issues may not persist, reflecting expectations for a return to normal pricing.
- Economic Impact Assessment: Despite the pressure from rising oil prices, recent employment data shows a decrease in unemployment, suggesting that consumer confidence remains strong, which may mitigate the negative effects of higher oil prices on the economy.
- Space Economy Potential: SpaceX is seeking a confidential public listing with a potential valuation of $2 trillion; however, the actual funds needed may be significantly lower, indicating strong investor interest in the space sector and its growth prospects.
See More
Salesforce's Transformation and Challenges in the Age of AI
- Cost-Saving Strategy: Morgan DeBaun, CEO of Blavity, anticipates a shift from Salesforce's CRM platform to a more cost-efficient AI solution by early 2027, potentially saving 50% to 60%, highlighting the emphasis on cost-effectiveness in the AI era.
- Expectations for AI Features: DeBaun insists that Salesforce's AI capabilities should be included in the base offering rather than charged separately, indicating dissatisfaction with pricing strategies that could impact Salesforce's competitive position in the market.
- Market Reaction and Stock Volatility: Salesforce's stock has dropped over 35% in the past year, currently trading around $170, reflecting investor concerns about AI tools potentially disrupting traditional enterprise software, leading to a broader sell-off in software stocks.
- Future Outlook and Investment Confidence: Despite challenges, analysts remain bullish on Salesforce, with Citizens maintaining a buy rating and a $315 price target, demonstrating confidence in the company's ability to adapt to the evolving AI landscape.
See More
CDC Report Delay Raises Questions on Vaccine Efficacy
- Vaccine Efficacy Report Delayed: CDC's Jay Bhattacharya has postponed the publication of a report originally scheduled for March 19, which indicated that COVID vaccines could reduce the risk of ER visits and hospitalizations by nearly 50% in healthy adults, raising concerns about vaccine efficacy.
- Methodology Controversy: The study utilized a 'test-negative design' based on data from healthy adults receiving the 2025-2026 vaccine, showing a 50% and 55% reduction in ER visits and hospitalizations, respectively; however, Bhattacharya's concerns about the methodology may undermine public confidence in vaccines.
- Political Interference Concerns: A former CDC official suggested that the vaccine benefits are being downplayed due to the stance of HHS Secretary RFK Jr., who has pushed for restrictions on vaccine availability, potentially affecting the CDC's research publication and public health policy.
- Leadership Review Norm: An HHS spokesperson noted that it is routine for CDC leadership to review and flag concerns regarding study methodologies before publication, highlighting the complex interplay between science and politics in vaccine research dissemination.
See More
